The news: Health insurer Highmark Health will cover the cost of Noom’s weight management programs as part of plan members’ medical benefits starting next year.
Digging into the details: Eligible Highmark members can opt into an initial…
Blog
-
Ontario’s $100 Billion Pension Dismisses Entire Asia Buyout Team
Ontario Municipal Employees Retirement System is cutting its Asia buyout team, marking the latest change in the pension fund’s private equity unit as it reassesses its strategy.
The Singapore-based private equity team for the region has a handful of members, according to people with knowledge of the matter who asked not to be identified because the details are confidential. The decision will be effective Dec. 31.
Continue Reading
-
Crude futures settle lower
NEW YORK, Oct. 24 (Xinhua) — Oil prices declined on Friday.
The West Texas Intermediate for December delivery dropped 28 cents, or 0.47 percent, to settle at 61.50 U.S. dollars a barrel on the New York Mercantile Exchange. Brent crude for December delivery lost 5 cents, or 0.08 percent, to settle at 65.94 dollars a barrel on the London ICE Futures Exchange. Enditem
Continue Reading
-
Sora Has Lost Its App Store Crown to Drake and Free Chicken
Since its launch on September 30, OpenAI’s Sora app has dominated the iOS App Store charts, thanks to its easy breezy AI video generation and an initially loose interpretation of copyright laws. On Friday, its reign came to an end. Your new…
Continue Reading
-
Afghan transit trade to remain shut till evaluation of security situation: FO
Spokesperson says national security and protection of Pakistani citizens are more important than any trade activity
Foreign Office Spokesperson Tahir Hussain Andrabi. PHOTO: Radio Pakistan
…Continue Reading
-
Hailey Bieber fiercely breaks silence on shocking rumours
Hailey Bieber has shut down…
Continue Reading
-
How to access Windows 11 BIOS configuration with hotkeys
As organizations move fully to Windows 11, consistent access to and control over firmware settings is becoming a governance and security concern, not just a troubleshooting task. Enterprise IT leaders and endpoint managers need clear, repeatable…
Continue Reading
-
Camila Cabello to Honor Grandmother at Carlos Eric Lopez’s Día De Muertos
Camila Cabello landed on the Billboard Hot 100 with “First Man,” a song dedicated to her father Alejandro, who broke down in tears when she wowed the Grammys with a live performance in 2020. Next week, she’ll turn her attention to her…
Continue Reading
-
New epimodulation approach improves outbreak forecasts
During an epidemic, some of the most critical questions for healthcare decision-makers are the hardest ones to answer: When will the epidemic peak, how many people will need treatment at once and how long will that peak level of…
Continue Reading
-
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
The FDA has approved revumenib (Revuforj; Syndax Pharmaceuticals) for patients 1 year and older with relapsed or refractory
acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation if there are no other satisfactory treatment options.1The
approval was based on data from the phase 2 AUGMENT-101 (NCT04065399 ) trial, which found the rate of complete remission (CR) plus CR with partial hematological recovery (CRh) was 23.4% (95% CI, 13.8%-35.7%; P = .0014), according to the datapublished in May in Blood .2 Updated data presented at the 2025annual meeting of the European Hematology Association (EHA) in June showed a CR/CRh rate of 25%.3According to the updated results presented at EHA, the median time to first CR/CRh was 2.8 months with a median duration of 4.7 months. The overall response rate was 48.1%.
“The expanded FDA approval of Revuforj marks a major advancement in the management of acute leukemia patients,” Joshua F. Zeidner, MD, chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center, said in a
statement .4 “For the first time, a targeted, oral therapy that is well tolerated and efficacious is approved for R/R NPM1-mutated AML and R/R KMT2A-translocated acute leukemia. The compelling clinical activity observed with Revuforj in clinical trials and clinical practice paves the way for a new standard of care for these 2 aggressive and difficult-to-treat blood cancers.”Examining Revumenib: Highlighting Efficacy and Adverse Events
The data published in Blood also showed that responses were observed across various subgroups, regardless of previous hematopoietic stem cell transplantation (HSCT) and number of lines of therapy.2 CR/CRh rates were also similar among adults younger than 65 years or 65 years and older. Patients with previous venetoclax exposure had a CR/CRh rate of 16.7% (95% CI, 7.5%-30.2%), while patients without previous exposure had a CR/CRh rate of 43.8% (95% CI, 19.8%-70.1%).
There were 5 adult patients who achieved an overall response and underwent allogeneic HSCT while in remission, with 3 of them subsequently resuming revumenib after transplant.
In addition, 98.8% of patients experienced treatment-emergency adverse events (AEs), with 78.6% experiencing at least 1 treatment-related AE (TRAE) and 59.5% experiencing a grade 3 or higher TRAE.
Additional safety findings were:
- 76.2% of patients required a dose modification
- 66.7% of patients required a dose interruption
- 11.9% of patients requiring a dose reduction due to TRAEs
- The most common TRAEs were QTcF prolongation (42.9%), vomiting (36.9%), febrile neutropenia (34.5%), hypokalemia (32.1%), nausea (28.6%), anemia (27.4%), diarrhea (27.4%), fatigue (23.8%), pyrexia (23.8%), epistaxis (21.4%), and peripheral edema (21.4%)
“New treatment options are vitally needed for patients with NPM1-mutated AML whose disease has returned or not improved after previous treatment,” said Lore Gruenbaum, PhD, chief scientific officer of Blood Cancer United (formerly The Leukemia & Lymphoma Society). “The FDA approval of a precision treatment that selectively targets the pathway driving this form of AML offers new hope to patients and their loved ones.”
Revumenib was previously approved in 2024 to treat R/R acute leukemia with a KMT2A translocation for patients 1 year and older.5
References
1. FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. News release. FDA. October 24, 2025. Accessed October 24, 2025.
https://www.cancernetwork.com/view/fda-approves-revumenib-in-r-r-npm1-mutant-aml 2. Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. Published online May 7, 2025. Accessed May 8, 2025. doi:10.1182/blood.2025028357
3. Joszt L. Revumenib shows efficacy in patients with AML and genetic alterations. AJMC®. June 12, 2025. Accessed October 24, 2025.
https://www.ajmc.com/view/revumenib-shows-efficacy-in-patients-with-aml-and-genetic-alterations 4. Syndax announces FDA approval of Revuforj (revumenib) in adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemia. News release. Syndax Pharmaceuticals. October 24, 2025. Accessed October 24, 2025.
https://ir.syndax.com/news-releases/news-release-details/syndax-announces-fda-approval-revuforjr-revumenib-adult-and 5. Rosa K. FDA approves revumenib for R/R acute leukemia with a KMT2A translocation. OncLive®. November 15, 2204. Accessed October 24, 2025.
https://www.onclive.com/view/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation Continue Reading